BR112023025403A2 - Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo - Google Patents
Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmoInfo
- Publication number
- BR112023025403A2 BR112023025403A2 BR112023025403A BR112023025403A BR112023025403A2 BR 112023025403 A2 BR112023025403 A2 BR 112023025403A2 BR 112023025403 A BR112023025403 A BR 112023025403A BR 112023025403 A BR112023025403 A BR 112023025403A BR 112023025403 A2 BR112023025403 A2 BR 112023025403A2
- Authority
- BR
- Brazil
- Prior art keywords
- heterocyclic compound
- ubiquitin
- same
- pathway
- function
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 4
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 230000015556 catabolic process Effects 0.000 title abstract 3
- 238000006731 degradation reaction Methods 0.000 title abstract 3
- 102000044159 Ubiquitin Human genes 0.000 title 1
- 108090000848 Ubiquitin Proteins 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo. a presente invenção refere-se a um composto heterocíclico e a uma composição para prevenir ou tratar um câncer, uma doença autoimune e uma doença inflamatória, compreendendo o mesmo. o novo composto heterocíclico da presente invenção é um composto bifuncional com função de degradação da tirosina quinase de bruton (btk) através de uma via do proteassoma da ubiquitina e pode ser usado como uma composição para prevenir ou tratar um câncer, uma doença autoimune e doença de parkinson.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210083326 | 2021-06-25 | ||
| KR1020220077174A KR102637915B1 (ko) | 2021-06-25 | 2022-06-23 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
| PCT/KR2022/009087 WO2022270994A1 (ko) | 2021-06-25 | 2022-06-24 | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025403A2 true BR112023025403A2 (pt) | 2024-02-20 |
Family
ID=84544657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025403A BR112023025403A2 (pt) | 2021-06-25 | 2022-06-24 | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4361153A1 (pt) |
| AU (1) | AU2022297176A1 (pt) |
| BR (1) | BR112023025403A2 (pt) |
| CA (1) | CA3223447A1 (pt) |
| WO (1) | WO2022270994A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023242597A1 (en) * | 2022-06-16 | 2023-12-21 | Amphista Therapeutics Limited | Bifunctional molecules for targeted protein degradation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008147831A1 (en) | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
| MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| JP7009466B2 (ja) | 2016-10-11 | 2022-02-10 | アルビナス・オペレーションズ・インコーポレイテッド | アンドロゲン受容体の標的分解のための化合物および方法 |
| EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
| EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE |
| WO2018208132A1 (en) * | 2017-05-12 | 2018-11-15 | Korea Research Institute Of Chemical Technology | Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient |
| KR102128018B1 (ko) | 2017-05-12 | 2020-06-30 | 한국화학연구원 | 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물 |
| CN109422752B (zh) * | 2017-09-03 | 2023-04-07 | 上海美志医药科技有限公司 | 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物 |
| CN111542321A (zh) | 2018-01-02 | 2020-08-14 | 细胞基因公司 | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的同位素体 |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| TW201945357A (zh) | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
| WO2019186358A1 (en) | 2018-03-26 | 2019-10-03 | Novartis Ag | 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives |
| CN108959540A (zh) | 2018-06-30 | 2018-12-07 | 广东技术师范学院 | 一种用于隐性关联知识发现的多关系融合方法及智能化系统 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020038415A1 (en) | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 |
| JP2022500368A (ja) | 2018-09-07 | 2022-01-04 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法 |
| CN113412259A (zh) | 2018-10-15 | 2021-09-17 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2020214802A1 (en) | 2019-01-29 | 2021-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP3917517A4 (en) | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | CONNECTIONS AND USES THEREOF |
| WO2020162725A1 (ko) | 2019-02-07 | 2020-08-13 | 한국화학연구원 | 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EP3924350A1 (en) | 2019-02-13 | 2021-12-22 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2020200291A1 (en) | 2019-04-02 | 2020-10-08 | Cullgen (Shanghai) , Inc. | Compounds and methods of treating cancers |
| WO2020263935A1 (en) | 2019-06-24 | 2020-12-30 | Dana-Farber Cancer Institute, Inc. | Hck degraders and uses thereof |
| WO2021058017A1 (en) | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用 |
-
2022
- 2022-06-24 BR BR112023025403A patent/BR112023025403A2/pt unknown
- 2022-06-24 CA CA3223447A patent/CA3223447A1/en active Pending
- 2022-06-24 WO PCT/KR2022/009087 patent/WO2022270994A1/ko active Application Filing
- 2022-06-24 EP EP22828841.1A patent/EP4361153A1/en active Pending
- 2022-06-24 AU AU2022297176A patent/AU2022297176A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022270994A1 (ko) | 2022-12-29 |
| AU2022297176A1 (en) | 2024-01-04 |
| EP4361153A1 (en) | 2024-05-01 |
| CA3223447A1 (en) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| Duan et al. | Targeting A-type K+ channels in primary sensory neurons for bone cancer pain in a rat model | |
| SV2008002963A (es) | Triazolopiridazinas como moduladores de tirosina cinasa referencia cruzada con solicitudes relacionadas ref. prd2584sv | |
| BR0317110A (pt) | Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| ECSP22083904A (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| BRPI0507744A (pt) | caracterìsticas de vestimenta absorvente para eliminação de arqueamento | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| BR112023025403A2 (pt) | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| BR112022002532A2 (pt) | Compostos heterocíclicos como inibidores de quinase | |
| NI201500148A (es) | USO DE 2, 3-DIHIDROIMIDAZO [1, 2-c] QUINAZOLINAS SUSTITUIDAS PARA TRATAR LINFOMAS | |
| ES2063073T3 (es) | Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios. | |
| Cai et al. | The STAT3 inhibitor pimozide impedes cell proliferation and induces ROS generation in human osteosarcoma by suppressing catalase expression | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| UY28522A1 (es) | Derivados de quinazolina | |
| BRPI0911681B8 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula in vitro | |
| GT200600254A (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
| CL2012001072A1 (es) | Compuestos derivados de feniletinilo, moduladores alostericos positivos del receptor de glutamato (mglur5); procedimiento de preparacion; composicion farmaceutica; y uso para tratar esquizofrenia o enfermedades cognitivas. | |
| BR112023021265A2 (pt) | Moduladores da proteólise de bcl6 e métodos de uso associados | |
| CL2022002978A1 (es) | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 | |
| UY29588A1 (es) | Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina |